RT Journal Article
SR Electronic
T1 A Complement Atlas identifies interleukin 6 dependent alternative pathway dysregulation as a key druggable feature of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.25.23287712
DO 10.1101/2023.03.25.23287712
A1 Van Damme, Karel F.A.
A1 Hoste, Levi
A1 Declercq, Jozefien
A1 Leeuw, Elisabeth De
A1 Maes, Bastiaan
A1 Martens, Liesbet
A1 Colman, Roos
A1 Browaeys, Robin
A1 Bosteels, Cédric
A1 Verwaerde, Stijn
A1 Vermeulen, Nicky
A1 Lameire, Sahine
A1 Debeuf, Nincy
A1 Deckers, Julie
A1 Stordeur, Patrick
A1 Guilliams, Martin
A1 Schetters, Sjoerd T.T.
A1 Haerynck, Filomeen
A1 Tavernier, Simon J.
A1 Lambrecht, Bart N.
YR 2023
UL http://medrxiv.org/content/early/2023/03/27/2023.03.25.23287712.abstract
AB To improve COVID-19 therapy, it is essential to understand the mechanisms driving critical illness. The complement system is an essential part of innate host defense that can also contribute to injury. All complement pathways have been implicated in COVID-19 pathogenesis, however the upstream drivers and downstream consequences on tissue injury remain ill-defined. Here, we demonstrate that complement activation is mediated by the alternative pathway and we provide a comprehensive atlas of the alterations in complement around the time of respiratory deterioration. Proteome and single-cell sequencing mapping across cell types and tissues reveals a division of labor between lung epithelial, stromal and myeloid cells in the production of complement, in addition to liver-derived factors. Upstream, IL-6 drives complement responses, linking complement dysregulation to approved COVID-19 therapies. In an exploratory proteomic study, C5 inhibition improves epithelial damage and markers of disease severity. Collectively, these results identify complement dysregulation as a key druggable feature of COVID-19.Competing Interest StatementBNL received consulting fees from Sanofi and GSK and holds stock options from Argenx. All remaining authors do not report conflicts of interest.Funding StatementVIB Tech Watch Fund supported the Olink proteomics (proximity extension analysis). The biomarker studies were funded by the VIB Grand Challenges program (M901BALA -GCP-COVID-19-SARPAC TRIAL and M902BALA-GCP-COVID-19-IL6-IL1 TRIAL). The single-cell CITE-seq profiling of BAL cells was funded through the Chan Zuckerberg Initiative (CZI) Covid atlas project (2020-216717), UGent COVID grant Covid-Track project (BOFCOV; 01C04620), FWO COVID grant Covid-Trace project (G0G4520N), and Ghent University GOA project (01G02418). Partner Therapeutics provided study medication for the SARPAC trial. COV-AID was funded by the Belgian Health Care Knowledge Center. The ZILUCOV trial was funded by UCB. Long-term follow-up of all trial participants was supported by a Ghent University Hospital grant (BOFCOV2020000801). KVD, LH, JD, EDL are beneficiaries of FWO predoctoral fellowships. STTS and SJT are supported by FWO postdoctoral fellowships, and STTS received funding from NWO (452019321). BNL received an European Research Council Advanced Grant (ERC-2017-ADG-789384), several FWO grants and a University of Ghent Methusalem Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies were approved by the competent authorities and the Ethical Committee of Ghent University Hospital, and all trials were conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.